HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer

Table 1 The relationship between frequency of HPV16 E6 or E7-specific T cell response in peripheral blood and clinical features in CSCC patients

Factor	N	E6-peptide specific T cell response		E7-peptide specific T cell response
Factor	N	Frequency (%)	P-value	Frequency (%)	P-value
Age (years)
≤ 55	38	52.63	0.105	31.58	0.807
> 55	38	34.21		34.21
Stage
IIb	45	37.78	0.232	35.56	0.552
IIIa-b	31	51.61		29.03
Tumor size (cm)
< 5	40	37.50	0.272	35.00	0.681
≥ 5	36	50.00		30.56
Tumor type
Cauliflower	33	45.45	0.859	27.27	0.338
Hollow	6	33.33		16.67
Nodular	37	43.24		40.54
Histologic grade
Poor	18	38.89	0.310	27.78	0.163
Moderate	46	45.65		34.78
Well	2	100		100
Papillary	10	33		20.00
HPV 16
Negative	14	50.00	0.582	42.86	0.380
Positive	62	41.93		30.64
TSGF
Normal	45	44.45	0.828	37.78	0.275
Abnormal	31	41.94		25.81
CEA
Normal	59	42.37	0.731	33.90	0.729
Abnormal	17	47.06		29.41
SCC
Normal	20	50.00	0.489	30.00	0.748
Abnormal	56	41.07		33.93
Pelvic lymph nodes
Negative	37	56.76	0.022	40.54	0.167
Positive	39	30.77		25.64

HPV, human papillomavirus; TSGF, tumour-specific growth factor; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma antigen

ISSN: 1750-9378